Somatotropin growth hormone recombinant human
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Idiopathic Short Stature
Conditions
Idiopathic Short Stature
Trial Timeline
Apr 1, 2006 → May 1, 2011
NCT ID
NCT00458263About Somatotropin growth hormone recombinant human
Somatotropin growth hormone recombinant human is a approved stage product being developed by Pfizer for Idiopathic Short Stature. The current trial status is completed. This product is registered under clinical trial identifier NCT00458263. Target conditions include Idiopathic Short Stature.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00458263 | Approved | Completed |
Competing Products
20 competing products in Idiopathic Short Stature